DermACELL®

Acellular dermal matrix

Dermacell is a decellularized regenerative human tissue matrix allograft processed using proprietary MATRACELL® technology from LifeNet Health.

  

LifeNet Health has over 30 years of experience in tissue processing and holds the longest-running accreditation with the American Association of Tissue Banks (AATB).1


DermACELL is
sterile and ≥97% donor DNA free

Sterility assurance level (SAL) 10-6 and ready to use - no rinsing required.

Dermacell is decellularized using Matracell, a proprietary and patented technology that removes at least 97% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.2

After being rendered acellular, Dermacell undergoes a terminal sterilization step to ensure a Sterility Assurance Level (SAL) of 10-6.

Low-dose gamma irradiation performed at ultra-low temperatures is used to reach surgical device-grade sterility, which lowers the probability of an active organism in the graft to 1 in 1,000,000.2

SPY Promise and
No Red Breast Promise

As a committed partner to hospitals and healthcare practitioners, we strive to provide innovative solutions for surgery and offer two promises with SPY and Dermacell. The SPY Promise provides replacement tissue at no cost if a revisionary surgery is required following simultaneous use of both SPY Fluorescence Imaging and Dermacell products. We also offer the No Red Breast Promise which grants a credit for Dermacell used in patients if they develop red breast syndrome following reconstruction surgery.


DermACELL Acellular Dermal Matrix

Sterile

Sterility assurance level (SAL) 10-6.2

 

Ready to use (RTU)

No rinsing required.2

 

≥97% Donor DNA-Free

A proprietary and patented technology that removes at least 87% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.2

 

Operative benefits

Dermacell provides a medical device-grade sterility assurance level of 10-6 and requires no rinsing prior to application.2 The graft features a wide suture border to further support intraoperative placement.

DermACELL PRS

Recent findings have demonstrated that the use of Dermacell Acellular Dermal Matrix (ADM) in immediate breast reconstruction has advantages over alternative ADMs including statistically significant improvement in number of days to drain removal and incidence of red breast syndrome.3

Pre-clinical evidence

Peer-reviewed, non-industry funded studies including Evaluation of Host Tissue Integration, Revascularization, and Cellular Infiltration within Various Dermal Substrates by Capito et al. reported that Dermacell was associated with the furthest cell infiltration and migration of all acellular dermal matrices studied.4

Clinical evidence

Dermacell is appropriate for a variety of patients, even those receiving postoperative chemotherapy, postoperative radiation, prednisone, or warfarin sodium.5